secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2025-08-27T23:59:59+00:00
Accession:  0001104659-25-083248
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quoin finalizes CFO exit: $433K lieu of notice, $108K bonus, extended options
-----------------------------------------------------------------------------

- Separation agreement signed August 21; effective August 15, 2025.
- Dunn receives $433,620 in bi-weekly installments in lieu of 12 months' notice.
- Additional $108,405 bonus for FY2024 paid in lump sum after 12 months.
- Vested stock options post-termination exercise period extended to 1 year 9 months from 90 days.
- Agreement includes mutual release of claims; no admission of liability.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925083248/0001104659-25-083248-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925083248/tm2524439d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-083248

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer